Ancient Chinese Herbal Formula Shows Promise Against Type 2 Diabetes Through a Cellular Recycling Pathway

A classical Chinese herbal formula that has been prescribed for centuries may owe its blood-sugar-lowering effects to a surprisingly modern molecular target: the cellular machinery that recycles damaged mitochondria. In a study published in the journal 3 Biotech, a team of researchers led by Lijuan Du and Shoujun Song of Binzhou Medical University set out to decode exactly how Banxia Xiexin decoction, a multi-herb formula long used in traditional Chinese medicine, acts on type 2 diabetes mellitus. Their findings, which combine computational network analysis with rigorous laboratory validation in diabetic mice, point to the activation of the AMPK/SIRT1 signaling axis and a process called mitophagy as the central mechanism by which the formula combats insulin resistance.

Type 2 diabetes mellitus is one of the most pressing health challenges of the modern era, affecting hundreds of millions of people worldwide and projected to increase in prevalence through 2050. At the heart of the disease lies insulin resistance, a state in which the body’s tissues respond poorly to the hormone insulin, causing blood glucose to climb. Scientists have increasingly recognized that insulin resistance is not simply a problem of too much sugar; it is driven by a web of interlocking disturbances, including chronic low-grade inflammation, oxidative stress caused by reactive molecules, and dysfunction of mitochondria, the tiny organelles that generate chemical energy within cells. When mitochondria falter, they leak damaging signals that further inflame tissues and worsen metabolic control, creating a vicious cycle that standard therapies often address only indirectly.

Banxia Xiexin decoction, known historically as a remedy for gastrointestinal disorders, has in recent years attracted attention for its clinical benefits in patients with type 2 diabetes. Earlier work by some of the same researchers had shown that the formula could protect insulin-producing pancreatic beta cells from apoptosis, or programmed cell death, by activating the PI3K/AKT/FOXO1 signaling pathway. Yet the full inventory of its active compounds and the precise molecular routes by which they influence metabolism remained obscure. The new study was designed to close that gap using an ambitious multi-pronged strategy that blends big-data biology with classical pharmacology and animal experimentation.

The first pillar of the approach was network pharmacology, a discipline that treats a drug and a disease as two overlapping networks of molecular interactions. The researchers mined databases of herbal medicine constituents, filtering compounds by oral bioavailability and drug-likeness, and then mapped the targets of those compounds against genes known to be involved in type 2 diabetes. The analysis revealed 217 targets shared between the formula and the disease. Among the most prominent hub proteins were the inflammatory messengers interleukin-1 beta and tumor necrosis factor alpha, the insulin-signaling kinase AKT1, the nuclear receptor PPARG, and the longevity-associated deacetylase SIRT1. Pathway enrichment analysis highlighted the AMPK signaling pathway, a master regulator of cellular energy balance, as a key route through which the formula might exert its effects.

Network pharmacology alone, however, can only suggest associations. To strengthen the causal case, the team turned to summary-data-based Mendelian randomization, a statistical technique that uses naturally occurring genetic variation as a kind of randomized trial conducted by nature. By examining whether genetically predicted differences in the expression of candidate target genes are associated with diabetes risk, the researchers could ask which of the network’s hub proteins actually drive the disease rather than merely accompany it. The analysis identified AKT1 and SIRT1 as being causally linked to type 2 diabetes risk, elevating these two proteins to the status of prime mechanistic suspects. Molecular docking simulations then tested whether the formula’s constituent molecules could physically bind these targets, and found that quercetin, kaempferol, and wogonin attached stably to the key proteins.

Identifying which compounds actually reach the bloodstream after the formula is swallowed was the next challenge. Using ultra-high-performance liquid chromatography coupled with Q-Orbitrap high-resolution mass spectrometry, the researchers analyzed serum from animals given the decoction. They detected 18 prototype compounds absorbed intact, along with 53 metabolites produced as the body chemically transformed the original constituents. This pharmacokinetic fingerprint confirmed that the compounds flagged by the computational screens, including the flavonoids quercetin and kaempferol and the flavone wogonin, are genuinely present in circulation, lending biological plausibility to the predicted drug-target interactions.

The decisive test came in living animals. The researchers induced diabetes in C57BL/6J mice using a combination of a high-fat diet and streptozotocin, a chemical that damages pancreatic beta cells and produces a metabolic picture closely resembling human type 2 diabetes. The diabetic mice were treated with Banxia Xiexin decoction for eight weeks, and the results were striking. Treated animals showed significantly lower fasting blood glucose and reduced HOMA-IR, a standard index of insulin resistance. Glucose tolerance tests and insulin tolerance tests both improved, with treated mice showing smaller areas under the response curves, indicating that their bodies regained sensitivity to insulin and handled dietary sugar more effectively.

The formula’s benefits extended beyond glucose control to the inflammatory and oxidative dimensions of the disease. Treated mice had reduced levels of tumor necrosis factor alpha, interleukin-1 beta, reactive oxygen species, and malondialdehyde, a lipid-damage marker, while the activity of superoxide dismutase, a natural antioxidant enzyme, was restored. Under the microscope, adipose tissue from treated animals retained healthier morphology than that of untreated diabetic controls, suggesting protection of fat tissue function, which is itself a critical determinant of whole-body insulin sensitivity. Together, these observations indicated that the decoction was not merely masking high blood sugar but was intervening in the underlying pathological processes that sustain the disease.

At the molecular level, the study’s mechanistic story centered on the AMPK/SIRT1 axis and mitophagy. AMP-activated protein kinase, or AMPK, acts as a cellular fuel gauge, switching on energy-conserving and quality-control programs when nutrients are scarce, while SIRT1, a sirtuin enzyme dependent on the molecule NAD+, coordinates metabolic adaptation and inflammation control. In the treated mice, the researchers observed activation of this pathway, accompanied by enhanced mitophagy, the selective autophagic removal of damaged mitochondria. Markers of this process shifted in a coherent direction: levels of PINK1 and Parkin, proteins that tag defective mitochondria for destruction, increased, as did the ratio of LC3-II to LC3-I, a hallmark of autophagosome formation, while p62, a cargo receptor that accumulates when autophagy is blocked, decreased. The formula also upregulated PPARG and phosphorylated AKT1, reinforcing insulin signaling in metabolic tissues.

The significance of this work lies not only in validating an ancient remedy but in demonstrating a template for how traditional medicine can be interrogated with modern tools. By triangulating between computational target prediction, genetic causal inference, serum pharmacokinetics, and controlled animal experiments, the researchers built a chain of evidence in which each link supports the next, reducing the risk that observed benefits are artifacts of any single method. The authors caution that their findings constitute mechanistic evidence supporting further translational investigation rather than proof of clinical efficacy, and the mouse model, while informative, cannot capture every facet of human diabetes. Nevertheless, the identification of the AMPK/SIRT1-mitophagy axis as a target of Banxia Xiexin decoction offers a concrete molecular hypothesis that can now be tested in human studies, potentially opening a path toward evidence-based integration of this centuries-old formula into the therapeutic arsenal against type 2 diabetes.

Subject of Research: Therapeutic mechanism of the traditional Chinese medicine formula Banxia Xiexin decoction in type 2 diabetes mellitus via the AMPK/SIRT1-mitophagy pathway

Article Title: Combining network pharmacology and experimental validation to explore the therapeutic mechanism of Banxia Xiexin decoction in type 2 diabetes mellitus

Article References: Du, L., Chen, Y., Zhang, X., Han, Y., Qin, G., Tang, Y., Han, S., Yang, Y., Zhao, Q., & Song, S. (2026). Combining network pharmacology and experimental validation to explore the therapeutic mechanism of Banxia Xiexin decoction in type 2 diabetes mellitus. 3 Biotech, 16(10), Article 406. https://doi.org/10.1007/s13205-026-05001-9

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05001-9

Keywords: type 2 diabetes mellitus, Banxia Xiexin decoction, network pharmacology, AMPK/SIRT1 pathway, mitophagy, insulin resistance, traditional Chinese medicine, quercetin, kaempferol, wogonin, Mendelian randomization, oxidative stress